A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression.
Saved in:
| Title: | A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression. |
|---|---|
| Authors: | Chapeau EA; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Mandon E; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Gill J; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland., Romanet V; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Ebel N; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Powajbo V; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Andraos-Rey R; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Qian Z; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Kininis M; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Zumstein-Mecker S; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Ito M; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Hynes NE; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland., Tiedt R; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Hofmann F; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Eshkind L; Institute for Translational Immunology and Research Center for Immunotherapy, University Medical Center, Johannes Gutenberg University, Mainz, Germany., Bockamp E; Institute for Translational Immunology and Research Center for Immunotherapy, University Medical Center, Johannes Gutenberg University, Mainz, Germany., Kinzel B; Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland., Mueller M; Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland., Murakami M; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Baffert F; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Radimerski T; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland. |
| Source: | PloS one [PLoS One] 2019 Oct 10; Vol. 14 (10), pp. e0221635. Date of Electronic Publication: 2019 Oct 10 (Print Publication: 2019). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1932-6203 |
|---|---|
| DOI: | 10.1371/journal.pone.0221635 |
